Perrigo's Consumer Self-Care Turnaround Faces a Heavily Shorted Float

Perrigo Company plc is a Dublin-domiciled, U.S.-operated consumer self-care company. It develops, manufactures, and markets store-brand (private label) and branded OTC health and wellness products, sold primarily through mass merchandisers, drugstores, supermarkets, and e-commerce channels in North America and Europe.

How it makes money. Perrigo sells to retailers, not to end consumers. Retailers contract with Perrigo to manufacture products that carry the retailer's own label at a price point typically 20–40% below the national brand equivalent. Perrigo earns a manufacturing and formulation margin on that volume, and its economics are driven by (1) unit volume through retail shelves, (2) manufacturing utilization across its plant network, and (3) input cost spreads on active pharmaceutical ingredients, packaging, and logistics.

Reporting segments. The business is organized principally around Consumer Self-Care Americas (CSCA) — the largest profit pool, covering OTC categories such as pain, cough/cold, allergy, and digestive health — and Consumer Self-Care International (CSCI), which carries the European store-brand and select branded portfolio. A smaller infant nutrition business has been the source of significant operational disruption and remediation spending.

Customers and scale. Perrigo's customer base is concentrated among a handful of large North American and European retailers, which creates negotiating leverage for buyers but also embeds Perrigo as a strategic supplier — retailers need a credible private-label alternative to keep national brand pricing honest. With a $2.0B market cap, 138.37M shares outstanding, and a public float of 138.07M — effectively the entire share count — the equity is fully liquid in structure but thinly traded in practice, with average volume of 3.17M shares.

Near-term (next 12–24 months). The primary near-term driver is not top-line growth but the elimination of drag. Annualizing out infant formula remediation costs, completing the divestiture of non-core assets, and stabilizing manufacturing utilization should allow reported gross margin to inflect. Volume growth in core OTC categories should track roughly in line with retail sell-through — low single digits — with modest share gains as retailers expand private-label shelf space in a value-conscious consumer environment. Debt reduction from divestiture proceeds is the second near-term lever, reducing interest expense and improving the equity's residual value.

Medium-term (3–5 years). The structural growth story for store-brand OTC is favorable: private label penetration in U.S. health and wellness remains below comparable European levels, and retailers have a permanent incentive to expand it. Perrigo's scale in formulation and regulatory approvals creates a barrier to entry that smaller private-label manufacturers cannot easily replicate. Medium-term growth should come from (1) category expansion into higher-value OTC segments, (2) geographic mix shift toward higher-margin European private label, and (3) operating leverage as volume recovers against a fixed manufacturing base. We model low-single-digit revenue growth with margin expansion doing the heavy lifting for earnings.

The table above illustrates the central dynamic: reported EPS has been overwhelmed by impairment charges, culminating in the trailing $-12.29 figure, while the underlying adjusted earnings power has compressed but remained positive. The gap between adjusted and reported EPS is the impairment and restructuring bridge. Our projections assume gross margin recovers from the mid-30s toward 40% as input costs normalize and remediation spending annualizes out, with operating margin expanding roughly 200–300bps per year off a depressed base. Reported EPS should converge toward adjusted EPS as the charge cycle completes — a mechanical improvement that does not require heroic revenue assumptions.

Market size. The global consumer self-care / OTC market is estimated in the range of $150–180B annually, with the North American store-brand OTC segment representing a meaningful single-digit-percentage slice of that total. Private-label OTC penetration in the U.S. is roughly in the mid-teens to low-twenties depending on category, versus materially higher penetration in several European markets — implying a long runway for share shift from national brands. Perrigo is the largest pure-play store-brand OTC manufacturer globally, giving it a scale advantage that is difficult to replicate.

Competitive positioning. Perrigo's moat rests on regulatory approvals (OTC monographs and equivalent European frameworks), formulation know-how across thousands of SKUs, and manufacturing scale that supports retailer economics. The principal vulnerability is customer concentration: a handful of retailers control shelf space, and their private-label programs are increasingly sourced from multiple vendors to maintain pricing tension.

Named comparables.

• Haleon (HLN) — the former GSK consumer health business; a branded-heavy OTC competitor with global scale and materially higher margins, useful as a quality benchmark.
• Kenvue (KVUE) — the former J&J consumer health spinoff; branded portfolio (Tylenol, Neutrogena) with strong U.S. retail relationships, a direct competitor for shelf space.
• Church & Dwight (CHD) — a hybrid branded/private-label consumer staples operator with a demonstrated ability to compound through cycles; a valuation reference for well-run consumer staples.
• Prestige Consumer Healthcare (PBH) — a smaller, branded OTC consolidator with a similar end-market exposure and a useful read on OTC asset multiples.

DCF discussion. A discounted cash flow model anchored on our base case — low-single-digit revenue growth, operating margin expanding from roughly 8% toward 13% over three years, and a weighted average cost of capital in the 8–9% range (supported by the 0.60 beta) — produces a fair value range that sits meaningfully above the current $14.57 price. The critical sensitivity is the margin bridge: if operating margin stalls near current levels, the DCF converges on today's price; if it reaches low-teens, the equity is worth roughly double. We weight the base case most heavily given the defensiveness of the underlying category and the self-limiting nature of the cost pressures.

Comparable multiples. The table below frames PRGO against named peers on a market-cap-relative basis. Note that PRGO's negative trailing EPS makes P/E non-meaningful on a reported basis; the multiple analysis therefore leans on adjusted earnings and sales.

PRGO trades at a fraction of the sales multiple of every named comparable despite operating in the same end market with a structurally similar demand profile. Even a partial re-rating toward the low end of the peer group would imply substantial upside from $14.57.

• Turnaround execution risk. Management has repeatedly guided toward margin recovery that has failed to materialize on schedule. Continued delays would validate the bear case and could drive the stock back toward the $9.23 52-week low.
• Customer concentration. A small number of large retailers control shelf space. Loss of a significant private-label contract, or aggressive vendor rotation, would pressure volumes and manufacturing utilization simultaneously.
• Input cost and supply chain volatility. Commodity, packaging, and freight costs remain unpredictable. A renewed inflationary spike would compress gross margin before the recovery takes hold.
• Regulatory and quality risk. OTC manufacturing is subject to stringent FDA and equivalent European oversight. Any facility warning letter, recall, or remediation event carries both financial cost and reputational damage — the infant formula experience is the template.
• Balance sheet and refinancing risk. Leverage remains elevated following years of acquisition activity. Rising rates or a credit rating downgrade would raise the cost of capital and constrain the divestiture-funded deleveraging plan.
• Short squeeze cuts both ways. With 24.93% of the float short, the equity is prone to violent moves in both directions. A disappointing quarter into that positioning could trigger a disorderly decline on thin liquidity.